VistaGen Therapeutics logo
VistaGen Therapeutics VTGN
$ 0.16 -15.79%
report update icon

Quarterly report 2027-Q2
added 11-13-2026

VistaGen Therapeutics Total Assets | VTGN

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets VistaGen Therapeutics

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999
48.6 M 84.3 M 124 M 21.1 M 74.6 M 108 M 5.77 M 14 M 11.3 M 3.71 M 990 K 270 K 264 K 882 K 342 K 324 K - - - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
124 M 264 K 31.2 M

Quarterly Total Assets VistaGen Therapeutics

2027-Q2 2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
23.4 M 35.7 M 48.6 M 65.1 M 80.9 M 68.9 M 84.3 M 92.3 M 102 M 114 M 124 M 131 M 42.2 M 15 M 21.1 M 42.2 M 15 M 21.1 M 74.6 M 29.7 M 58.7 M 58.7 M 90.5 M 100 M 104 M 104 M 109 M 20.3 M 6.17 M 12.9 M 5.33 M 8.74 M 12.9 M 14 M 11.3 M 14.2 M 8.26 M 2.44 M 3.71 M 2.62 M 2.44 M 3.71 M 990 K 7.02 M 7.02 M 8.76 M 270 K 1.93 M 1.74 M 270 K 264 K 387 K 765 K 765 K 329 K 329 K 406 K 432 K 264 K 425 K 645 K 645 K 882 K 537 K 1.68 M 1.68 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
131 M 264 K 30.7 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
Johnson & Johnson Johnson & Johnson
JNJ
199 B $ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
42.2 M $ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
359 M $ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
148 M $ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
379 M $ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
157 M $ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
258 M $ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
76.9 M $ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
583 M $ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
325 M $ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
113 M $ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
13.5 M $ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
112 B $ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
1.66 B $ 24.73 -1.9 % $ 783 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
20 M $ 0.32 1.02 % $ 2.52 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
168 M $ 2.05 -15.81 % $ 27.3 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
82.8 M $ 76.99 0.03 % $ 997 M usaUSA
Curis Curis
CRIS
20 M $ 0.44 -6.31 % $ 5.79 M usaUSA
CorMedix CorMedix
CRMD
826 M $ 5.25 4.23 % $ 378 K usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
146 M $ 3.07 -4.66 % $ 255 M usaUSA
Champions Oncology Champions Oncology
CSBR
27 M $ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
785 M $ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
843 M $ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
792 M $ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
9.95 M $ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
137 B $ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
12.3 B $ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
29.8 M $ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
111 B $ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
216 M $ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
324 M $ 3.69 -0.67 % $ 281 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
30.5 M $ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
571 M $ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
341 M $ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
259 M $ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
45.8 B $ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
172 M $ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
21.4 B $ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
328 M $ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
61.1 B $ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
45.6 M $ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
2.9 B $ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
4.5 M $ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
55.2 M $ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
683 M $ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
10.1 M $ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
6.96 B $ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
32.4 M $ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
493 B $ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
40.6 B $ 920.38 -0.22 % $ 96.3 B usaUSA